Literature DB >> 205366

Immunization of mice against murine mammary tumor virus infection and mammary tumor development.

N H Sarkar, D H Moore.   

Abstract

Formalin-inactivated whole murine mammary tumor virus (MuMTV), VuMTV membranes, the acid-soluble component of MuMTV, and purified MuMTV glycoprotein with a molecular weight of 55,000 (gp55; also designated as gp52) were used as vaccines in an attempt to identify the MuMTV antigen(s) that can protect mice from exogenous MuMTV infection and subsequent tumor development. Formalin-inactivated whole MuMTV, MuMTV membranes, and purified MuMTV gp55 were effective immunogens, whereas the acid-soluble component of MuMTV (which consists mainly of MuMTV gp55) failed to protect mice from challenge with live virus. These results suggest that (a) MuMTV gp55 is the major immunizing antigen and (b) its native conformation must be maintained for it to be an effective vaccine.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 205366

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  Natural and induced immunity to mouse mammary tumors and the mammary tumor virus (MuMTV).

Authors:  O Stutman
Journal:  Springer Semin Immunopathol       Date:  1982

Review 2.  Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein-Barr Virus (EBV).

Authors:  James S Lawson; Brian Salmons; Wendy K Glenn
Journal:  Front Oncol       Date:  2018-01-22       Impact factor: 6.244

3.  Rejection of murine mammary tumours in BALB/c mice.

Authors:  S Robidoux; A Kajdos; M Tomana; C W Niedermeier
Journal:  Br J Cancer       Date:  1979-01       Impact factor: 7.640

4.  In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters.

Authors:  Inken Salewski; Yvonne Saara Gladbach; Steffen Kuntoff; Nina Irmscher; Olga Hahn; Christian Junghanss; Claudia Maletzki
Journal:  J Transl Med       Date:  2020-10-21       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.